XNCR – Xencor Inc

Xencor, Inc.

XNCR

$40.10

Name : Xencor, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $3,009,091,328.00

EPSttm : -1.56

Xencor, Inc.

$40.10

1.80%

$0.71

XNCR — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

17.37

Margin Of Safety %

Put/Call OI Ratio

0.45

EPS Next Q Diff

-1.46

EPS Last/This Y

-1.1

EPS This/Next Y

-1.44

Price

39.41

Target Price

42.5

Analyst Recom

1.36

Performance Q

69.93

Upside

-152.5%

Beta

0.74

Ticker: XNCR

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-12	XNCR	25.05	0.47	0.31	7141
2026-10-13	XNCR	23.56	0.47	0.54	7145
2026-10-14	XNCR	23.42	0.52	0.00	18246
2026-10-15	XNCR	24.01	0.51	1.00	18294
2026-10-16	XNCR	22.82	0.51	0.00	18298
2026-10-19	XNCR	23.21	0.53	0.00	17795
2026-10-20	XNCR	24.97	0.53	0.88	17826
2026-10-21	XNCR	25.17	0.53	0.10	17844
2026-10-22	XNCR	25.83	0.53	0.00	17845
2026-10-23	XNCR	25.16	0.53	0.00	17845
2026-10-26	XNCR	29.21	0.49	0.31	18846
2026-10-27	XNCR	30	0.43	1.50	21972
2026-10-28	XNCR	29.98	0.43	0.32	21961
2026-10-29	XNCR	29.22	0.43	37.50	21892
2026-10-30	XNCR	29.79	0.44	6.27	21929
2026-11-02	XNCR	29.65	0.44	26.33	21921
2026-11-03	XNCR	30.62	0.44	0.64	21942
2026-11-04	XNCR	35	0.44	0.00	21942
2026-11-05	XNCR	34.05	0.42	0.39	22527
2026-11-06	XNCR	35.79	0.42	0.31	22526
2026-11-09	XNCR	38.6	0.42	3.39	22571
2026-11-10	XNCR	39.44	0.45	0.01	23144
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-12	XNCR	25.06	-100.0	-	-3.15
2026-10-13	XNCR	23.55	-100.0	-	-3.15
2026-10-14	XNCR	23.42	-100.0	-	-3.15
2026-10-15	XNCR	24.00	-100.0	-	-3.15
2026-10-16	XNCR	22.83	-100.0	-	-3.15
2026-10-19	XNCR	23.20	-100.0	-	-3.15
2026-10-20	XNCR	23.20	-100.0	-	-3.15
2026-10-21	XNCR	24.94	-100.0	-	-3.15
2026-10-22	XNCR	25.86	-100.0	-	-3.15
2026-10-23	XNCR	25.15	-100.0	-	-3.15
2026-10-26	XNCR	29.17	-100.0	-	-3.15
2026-10-27	XNCR	29.98	-100.0	-	-3.15
2026-10-28	XNCR	29.90	-100.0	-	-3.07
2026-10-29	XNCR	29.18	-100.0	-	-3.07
2026-10-30	XNCR	29.80	-100.0	-	-3.07
2026-11-02	XNCR	29.65	-100.0	-	-3.07
2026-11-03	XNCR	30.64	-100.0	-	-3.07
2026-11-04	XNCR	35.03	-100.0	-	-3.07
2026-11-05	XNCR	34.03	-100.0	-	-3.07
2026-11-06	XNCR	35.78	-100.0	-	-3.07
2026-11-09	XNCR	38.60	-100.0	-	-3.07
2026-11-10	XNCR	39.41	-100.0	-	-2.34
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-12	XNCR	-0.77	-0.55	23.39
2026-10-13	XNCR	-0.77	-0.55	23.39
2026-10-14	XNCR	-0.69	-0.55	23.39
2026-10-15	XNCR	-0.69	-0.55	23.39
2026-10-16	XNCR	-0.69	-0.55	23.39
2026-10-19	XNCR	-0.69	-0.59	23.39
2026-10-20	XNCR	-0.69	-0.59	23.39
2026-10-21	XNCR	-0.69	-0.59	23.39
2026-10-22	XNCR	-0.69	-0.59	23.39
2026-10-23	XNCR	-0.69	-0.59	23.39
2026-10-26	XNCR	-0.69	-0.52	23.39
2026-10-27	XNCR	-0.69	-0.52	17.53
2026-10-28	XNCR	-0.69	-0.52	17.53
2026-10-29	XNCR	-0.69	-0.52	17.53
2026-10-30	XNCR	-0.69	-0.52	17.53
2026-11-02	XNCR	-0.69	-4.86	17.53
2026-11-03	XNCR	-0.69	-4.86	17.53
2026-11-05	XNCR	-0.69	-4.86	17.53
2026-11-06	XNCR	-0.69	-4.86	17.53
2026-11-09	XNCR	-0.69	-5.28	17.37
2026-11-10	XNCR	-0.69	-5.28	17.37
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.5

Avg. EPS Est. Current Quarter

-0.95

Avg. EPS Est. Next Quarter

-0.96

Insider Transactions

-0.69

Institutional Transactions

-5.28

Beta

0.74

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

6.8

Max Drawdown 5-Year %

-83.2

Target Price

42.5

P/E

Forward P/E

PEG

P/S

14.74

P/B

5.25

P/Free Cash Flow

EPS

-1.59

Average EPS Est. Cur. Y

-2.34

EPS Next Y. (Est.)

-3.78

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-58.79

Relative Volume

0.76

Return on Equity vs Sector %

-47.3

Return on Equity vs Industry %

-27.6

EPS 1 7Days Diff

0.7

EPS 1 30Days Diff

0.81

EBIT Estimation

◆ XNCR Healthcare

$39.39

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

20/20

Pullback

4/25

Volume

9/15

Valuation

2/20

TP/AR

4/10

Options

8/10

RSI

81.6

Range 1M

94.8%

Sup Dist

7.4%

🚀

Momentum Growth

Ride accelerating trends

WEAK

Momentum

22/25

Growth

15/30

Estimates

2/20

Inst/Vol

4/15

Options

7/10

EPS Yr

-96.6%

EPS NY

-48.5%

52W%

96.8%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟡 HOLD +7.9% upside

Quality

6/30

Valuation

2/30

Growth

10/25

Stability

6/10

LT Trend

4/5

Upside

+7.9%

Quality

XNCR — P/E HistoricalBiotechnology

Xencor, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 260

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

XNCR

Latest News

—

Caricamento notizie per XNCR…

stock quote shares XNCR – Xencor Inc Stock Price stock today

news today XNCR – Xencor Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch XNCR – Xencor Inc yahoo finance google finance

stock history XNCR – Xencor Inc invest stock market

stock prices XNCR premarket after hours

ticker XNCR fair value insiders trading

XNCR – Xencor Inc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: XNCR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y